FOR IMMEDIATE RELEASE
May 14, 2019

NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response

Abstract will be presented at the 2019 American Thoracic Society (ATS) International Conference in Dallas

FT. WORTH, (May 14, 2019) — NanOlogy LLC, a clinical-stage oncology company, announced today that its abstract showing encouraging therapeutic effects from a preclinical pharmacology study on inhaled NanoPac® (submicron particle paclitaxel) for treatment of lung cancer has been accepted for presentation at the 2019 American Thoracic Society International Conference.

The abstract, entitled *Enhanced Tumor Regression and Immune Cell Infiltration by Inhaled Submicron Particle Paclitaxel in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer (NSCLC)*, will be presented at the conference on May 20th, 11:15 AM to 1:00 PM, during the Oncogenic Mutations, Metastases, and Novel Therapeutics poster session at the Kay Bailey Hutchison Convention Center in Dallas.

Previously, NanOlogy conducted a pharmacokinetic study examining retention of NanoPac in healthy rat lung tissue following a single inhalation via nose-only exposure chamber. Data showed measurable amounts of drug in lung tissue 14-days post exposure, with treated lungs microscopically indistinguishable from normal lung tissue. A preclinical proof-of-concept study was then conducted to examine the therapeutic effect of inhaled NanoPac in an orthotopic athymic nude rat model of NSCLC. An abstract of that study was presented at the 2018 ASCO Annual Meeting showing inhaled NanoPac achieved a significant decrease in primitive tumor cell population as well as significant tumor reduction.

The ATS abstract presents follow-on immunohistochemical analysis of lung tissue from the proof-of concept study, which showed NanoPac-treated animals had greater incidence and degree of tumor regression, immune cell infiltration, and tertiary lymphoid structures compared to untreated controls and intravenously administered *nab*-paclitaxel.

Describing the antitumoral immune response, Gere diZerega, MD, VP of Medical Affairs, observed, “Immunohistochemical analysis showed the immune cell infiltrates appeared to facilitate destruction of tumor and its conversion into small fibrin deposits.”

NanOlogy is finalizing preclinical work of inhaled NanoPac in preparation for an investigational new drug (IND) submission to the US FDA in mid-2019 to allow for clinical trials in NSCLC.

During the conference, NanOlogy has also been selected to participate in the International Society for Aerosols in Medicine/ATS Pre-Conference session on "Current Practice and Future Developments in Aerosol Medicine." The session will be held on Saturday, May 18, from 1 PM to 4 PM at the Omni Dallas Hotel Trinity Ballroom 5-7 (Level 3).

Lung cancer is by far the leading cause of cancer death in the United States according to the American Cancer Society with more than 143,000 deaths projected this year. More people die of lung cancer annually than breast, prostate, and colon cancers combined.

In addition to lung cancer, NanOlogy clinical programs are advancing in genitourinary, gastrointestinal, peritoneal, lung, and dermal cancers.

The NanOlogy submicron particle technology platform is based on a proprietary production process that reduces the size of taxane API crystals by up to 400 times into stable submicron particles of pure drug with exponentially increased surface area and unique geometry. The characteristics of the particles have recently been granted a composition of matter patent (US 9,814,685) valid in the US until 2036.

###

About NanOlogy

NanOlogy, LLC (www.nanology.us) is a private clinical stage oncology company formed in 2015 to finance and clinically develop a patented submicron particle technology platform for local, sustained delivery of therapeutic agents aimed at increasing their value in the treatment of cancer and related conditions.

Disclaimers

This announcement contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including statements about our product development, business, and other activities. Such statements are subject to the risks and uncertainties inherent in any pharmaceutical development program which may cause actual results to differ materially due to developmental, clinical trial, regulatory, market, competitive, technological, or other factors. All forward-looking statements are made as of the date of this announcement and the company disclaims any intent or obligation to update these statements. NanOlogy investigational drugs have not been proven to be safe and effective as required by U.S. FDA and have not been approved by FDA or any other jurisdiction for commercial distribution.

Media Contact

Dan Eramian
Opus Biotech Communications
danieleramian@comcast.net
425-306-8716

Charles Craig
Opus Biotech Communications
charles.s.craig@gmail.com
404-245-0591